Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis | 17 | 2025 | 554 | 4.280 |
Why?
|
| Mycobacterium tuberculosis | 6 | 2025 | 413 | 2.030 |
Why?
|
| Antitubercular Agents | 6 | 2025 | 264 | 1.460 |
Why?
|
| Tuberculosis, Pulmonary | 3 | 2023 | 229 | 1.360 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 4 | 2025 | 76 | 1.330 |
Why?
|
| Feces | 3 | 2025 | 755 | 1.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2025 | 540 | 0.970 |
Why?
|
| Emigrants and Immigrants | 1 | 2025 | 158 | 0.780 |
Why?
|
| Mass Screening | 5 | 2025 | 828 | 0.620 |
Why?
|
| Radiography | 1 | 2021 | 819 | 0.620 |
Why?
|
| Vaping | 1 | 2016 | 30 | 0.480 |
Why?
|
| Rifampin | 3 | 2025 | 120 | 0.480 |
Why?
|
| Universities | 1 | 2016 | 129 | 0.470 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2016 | 58 | 0.460 |
Why?
|
| Cigarette Smoking | 1 | 2016 | 80 | 0.460 |
Why?
|
| Europe | 3 | 2025 | 372 | 0.460 |
Why?
|
| Contact Tracing | 3 | 2025 | 56 | 0.440 |
Why?
|
| Uganda | 6 | 2025 | 98 | 0.440 |
Why?
|
| Transients and Migrants | 2 | 2025 | 26 | 0.430 |
Why?
|
| Sputum | 2 | 2025 | 116 | 0.430 |
Why?
|
| Students | 1 | 2016 | 263 | 0.420 |
Why?
|
| Sensitivity and Specificity | 3 | 2025 | 2140 | 0.350 |
Why?
|
| European Union | 3 | 2025 | 13 | 0.340 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 3760 | 0.300 |
Why?
|
| Cameroon | 5 | 2025 | 10 | 0.280 |
Why?
|
| Isoniazid | 2 | 2025 | 66 | 0.270 |
Why?
|
| Humans | 23 | 2025 | 131985 | 0.230 |
Why?
|
| Ukraine | 1 | 2025 | 10 | 0.230 |
Why?
|
| Population Surveillance | 2 | 2025 | 416 | 0.230 |
Why?
|
| Disease Notification | 1 | 2025 | 9 | 0.230 |
Why?
|
| Africa South of the Sahara | 1 | 2025 | 121 | 0.230 |
Why?
|
| Africa | 1 | 2025 | 135 | 0.220 |
Why?
|
| Child | 9 | 2025 | 25762 | 0.220 |
Why?
|
| Diarylquinolines | 1 | 2023 | 6 | 0.210 |
Why?
|
| Somalia | 1 | 2023 | 6 | 0.210 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2024 | 178 | 0.200 |
Why?
|
| HIV Infections | 3 | 2025 | 2035 | 0.200 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2024 | 827 | 0.180 |
Why?
|
| Public Health | 1 | 2023 | 281 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 309 | 0.160 |
Why?
|
| Posters as Topic | 1 | 2019 | 7 | 0.160 |
Why?
|
| France | 2 | 2017 | 88 | 0.160 |
Why?
|
| Mental Health | 1 | 2023 | 370 | 0.160 |
Why?
|
| Infant | 5 | 2025 | 13047 | 0.150 |
Why?
|
| Blood Specimen Collection | 1 | 2019 | 47 | 0.150 |
Why?
|
| Blood Culture | 1 | 2019 | 36 | 0.150 |
Why?
|
| Incidence | 2 | 2025 | 3378 | 0.150 |
Why?
|
| Female | 8 | 2025 | 70623 | 0.150 |
Why?
|
| Child, Preschool | 5 | 2025 | 14732 | 0.150 |
Why?
|
| Adolescent | 5 | 2025 | 20535 | 0.140 |
Why?
|
| Poverty | 1 | 2021 | 446 | 0.140 |
Why?
|
| Case-Control Studies | 1 | 2025 | 3410 | 0.140 |
Why?
|
| Vaccination Coverage | 1 | 2017 | 37 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2025 | 6569 | 0.130 |
Why?
|
| Male | 7 | 2025 | 64910 | 0.130 |
Why?
|
| Nursing Homes | 1 | 2017 | 97 | 0.130 |
Why?
|
| Vaccination | 2 | 2023 | 1018 | 0.130 |
Why?
|
| Binge Drinking | 1 | 2016 | 10 | 0.130 |
Why?
|
| Marijuana Smoking | 1 | 2016 | 32 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 1246 | 0.120 |
Why?
|
| Seasons | 1 | 2017 | 327 | 0.120 |
Why?
|
| Pandemics | 1 | 2023 | 1183 | 0.110 |
Why?
|
| Depression | 1 | 2023 | 1339 | 0.110 |
Why?
|
| Motivation | 1 | 2016 | 330 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2018 | 370 | 0.100 |
Why?
|
| Family Characteristics | 2 | 2025 | 93 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 900 | 0.100 |
Why?
|
| Health Behavior | 1 | 2016 | 399 | 0.100 |
Why?
|
| Adult | 5 | 2025 | 31547 | 0.100 |
Why?
|
| DNA, Bacterial | 2 | 2024 | 494 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2018 | 822 | 0.100 |
Why?
|
| Influenza Vaccines | 1 | 2017 | 498 | 0.090 |
Why?
|
| Health Personnel | 1 | 2017 | 543 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2017 | 699 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2017 | 3991 | 0.080 |
Why?
|
| Middle Aged | 3 | 2025 | 28976 | 0.080 |
Why?
|
| Young Adult | 2 | 2024 | 9952 | 0.060 |
Why?
|
| Mozambique | 1 | 2024 | 22 | 0.050 |
Why?
|
| Community Health Workers | 1 | 2025 | 75 | 0.050 |
Why?
|
| Tanzania | 1 | 2024 | 74 | 0.050 |
Why?
|
| Tuberculosis Vaccines | 1 | 2023 | 13 | 0.050 |
Why?
|
| United Kingdom | 1 | 2023 | 235 | 0.050 |
Why?
|
| BCG Vaccine | 1 | 2023 | 112 | 0.050 |
Why?
|
| Coinfection | 1 | 2025 | 189 | 0.050 |
Why?
|
| Retrospective Studies | 1 | 2021 | 17391 | 0.050 |
Why?
|
| Consensus | 1 | 2025 | 649 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2025 | 1179 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 576 | 0.040 |
Why?
|
| Egypt | 1 | 2018 | 30 | 0.040 |
Why?
|
| Global Health | 1 | 2023 | 644 | 0.040 |
Why?
|
| Sofosbuvir | 1 | 2018 | 21 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2018 | 44 | 0.040 |
Why?
|
| Carbamates | 1 | 2018 | 68 | 0.030 |
Why?
|
| Prevalence | 1 | 2025 | 2658 | 0.030 |
Why?
|
| Ribavirin | 1 | 2018 | 89 | 0.030 |
Why?
|
| Valine | 1 | 2018 | 111 | 0.030 |
Why?
|
| Imidazoles | 1 | 2018 | 219 | 0.030 |
Why?
|
| Workplace | 1 | 2017 | 82 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2023 | 8542 | 0.020 |
Why?
|
| Aged | 1 | 2017 | 21415 | 0.010 |
Why?
|